ZhenGe Biotech is a biologics contract development and manufacturing organisation supporting the development and manufacturing of drugs from the pre-clinical stage to commercial-stage manufacturing.
* Sofina has an observer seat in the decision-making bodies of the company.
Established in 2017, ZhenGe Biotech is a fast-growing biologics CDMO based in Shanghai, China, that provides end-to-end, one-stop shop solutions to clients for the contract development and manufacturing of biologics from the pre-clinical stage to providing end-to-end solutions from concept to commercial-stage manufacturing. To date, the company has served more than 100 biopharma and biotech customers and has completed over 150 projects, ranging from cell line development projects to Investigational New Drug applications and large clinical phase production contracts. Over the years, ZhenGe Biotech has developed deep expertise across monoclonal and bispecific antibodies, Antibody Drug Conjugates, fusion proteins and vaccines.
Sofina invested in ZhenGe Biotech in 2021, notably next to LYFE Capital and Qiming.
China | 2021